�After failure of 1st generation thrombopoietic growth factors due to
immunogencity, the 2nd generation is focused on unwritten TPO mimetics, now
followed by a 3rd coevals of engineered biologics with potential for
higher strength and efficacy
The Business Intelligence firm La Merie S.L. reported in its most recent
line update of thrombopoiesis exhilarating agents that eight
thrombopoietin (TPO) mimetics are in clinical stages of development. The 2
most
